Next Article in Journal
Comparing the Japanese Version of the Ocular Surface Disease Index and Dry Eye-Related Quality-of-Life Score for Dry Eye Symptom Assessment
Next Article in Special Issue
Combining Point-of-Care Diagnostics and Internet of Medical Things (IoMT) to Combat the COVID-19 Pandemic
Previous Article in Journal
Tumor Multifocality is a Significant Risk Factor of Urinary Bladder Recurrence after Nephroureterectomy in Patients with Upper Tract Urothelial Carcinoma: A Single-Institutional Study
Previous Article in Special Issue
Point-of-Care RNA-Based Diagnostic Device for COVID-19
Open AccessEditorial

In Vitro Diagnostic Assays for COVID-19: Recent Advances and Emerging Trends

Pictor Private Limited, 24 Balfour Road Parnell, 1052 Auckland, New Zealand
Diagnostics 2020, 10(4), 202; https://doi.org/10.3390/diagnostics10040202
Received: 2 April 2020 / Revised: 3 April 2020 / Accepted: 3 April 2020 / Published: 5 April 2020
There have been tremendous advances in in vitro diagnostic (IVD) assays for coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The main IVD assays used for COVID-19 employ real-time reverse transcriptase polymerase chain reaction (RT-PCR) that takes a few hours. But the assay duration has been shortened to 45 min by Cepheid. Of interest is the point-of-care (POC) molecular assay by Abbott that decreased the assay duration to just 5 min. Most molecular tests have been approved by the United States Food and Drug Administration (FDA) under emergency use authorization (EUA) and are Conformité Européenne (CE) marked. A wide range of serology immunoassays (IAs) have also been developed that complement the molecular assays for the diagnosis of COVID-19. The most prominent IAs are automated chemiluminescent IA (CLIA), manual ELISA, and rapid lateral flow IA (LFIA), which detect the immunoglobulin M (IgM) and immunoglobulin G (IgG) produced in persons in response to SARS-CoV-2 infection. The ongoing research efforts and advances in complementary technologies will pave the way to new POC IVD assays in the coming months. However, the performance of IVD assays needs to be critically evaluated before they are employed for the clinical diagnosis of COVID-19. View Full-Text
Keywords: SARS-CoV-2; COVID-19; diagnostics; real-time reverse transcriptase polymerase chain (RT-PCR); lateral flow immunoassay (LFIA); immunoassays; point-of-care (POC) SARS-CoV-2; COVID-19; diagnostics; real-time reverse transcriptase polymerase chain (RT-PCR); lateral flow immunoassay (LFIA); immunoassays; point-of-care (POC)
Show Figures

Figure 1

MDPI and ACS Style

Vashist, S.K. In Vitro Diagnostic Assays for COVID-19: Recent Advances and Emerging Trends. Diagnostics 2020, 10, 202.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop